MYGN
Overvalued by 314.4% based on the discounted cash flow analysis.
Market cap | $358.55 Million |
---|---|
Enterprise Value | $405.95 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-3.18 |
Beta | 2.02 |
Outstanding Shares | 90,900,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.05 |
---|---|
PEG | 4.77 |
Price to Sales | 0.46 |
Price to Book Ratio | 0.51 |
Enterprise Value to Revenue | 0.49 |
Enterprise Value to EBIT | -3.66 |
Enterprise Value to Net Income | -4 |
Total Debt to Enterprise | 0.36 |
Debt to Equity | 0.2 |
No data
No data
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...